Dinners with Irwin: Mentorship, the Work Force, and the Future of Academic Dermatology  by Resneck, Jack S. & Kimball, Alexa Boer
COMMENTARY
 www.jidonline.org 529
ed and translational research. Some of 
these K23 (early) and K24 (mid-career) 
grants have made a large difference in 
sustaining individuals in their academic 
careers. The Veterans Administration 
has long recognized the need for trans-
lational and outcomes research in their 
funding mechanisms.
We are in the early years of a revolu-
tion in the therapies that will be avail-
able in medical dermatology. We have 
already seen the impact of new drug 
development on psoriasis and cuta-
neous T-cell lymphoma. With many 
new immunomodulatory drugs in the 
pipeline, our challenge is to fund the 
infrastructure that will allow studies of 
other diseases in medical dermatology. 
This requires funding to protect the 
time that people spend in academics 
so they can not only care for patients 
with complex diseases but advance 
the field with the clinical and trans-
lational studies needed to evaluate 
these new therapies. There is so much 
exciting work to be done, and if we 
capture these opportunities, it will sus-
tain and develop these aspects of our 
field. Opportunities to go from bench 
to bedside research are clear, but there 
are opportunities to go from bedside to 
bench that will require individuals with 
a true commitment to caring for those 
with dermatologic diseases to gather 
the insights that will stimulate further 
basic discoveries (Holcombe, 2005). 
We need to develop a broader work 
force in medical dermatology whose 
members are sustained over a lifetime 
of contributions. Those who choose 
cognitive careers must be given the 
time to exercise creativity and advance 
the field. The benefits to our field and 
our patients will be obvious, and if the 
opportunities are there, we will have 
no trouble attracting a new generation.
What do we need to do for the 
future? We need more funding models 
to sustain our academic work force in 
the area of medical dermatology. This 
can be done through private founda-
tions, endowed chairs, and increased 
governmental grant support. We need 
funding to link centers together to sys-
tematically study our less common dis-
eases. At a time when there is potential 
pharmaceutical interest of importance 
to our patients and our field, we lack 
outcome measures and expertise in 
many diseases. We risk losing our dis-
eases to other fields if we don’t quickly 
address these issues. The lack of out-
come measures in cutaneous lupus 
erythematosus was recently addressed, 
but the new tools will not be used in 
dermatology without development of 
more dermatology centers with both 
clinical expertise and the ability to 
perform trials (Albrecht et al., 2005). 
Our combined med–derm programs 
will, with the requisite interdigitation 
of training, build bridges to other fields 
that will allow us to interface more 
effectively. We need to develop and 
maintain a prominent place within the 
academic hospital. This requires car-
ing for sicker patients; having residents 
who are properly trained and inter-
ested in providing necessary in-patient 
coverage; and renewing our commit-
ment to this important component of 
our field. This particular goal will not 
be achieved easily and will require a 
critical mass of dedicated individuals 
that we now lack. The idea of short-
term return on investment — what 
medical centers frequently want to 
see for allocation of funds — will not 
work, and we need creative develop-
ment of new forms of funding.
Many young people are entering 
dermatology who would be thrilled at 
the opportunity to rebuild medical der-
matology. We need to provide them, 
and their future patients, with the 
opportunities to succeed. I am sure that 
Irwin, had he not experienced such an 
untimely death, would have continued 
to champion this important aspect of 
our field.
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Absolutely no one cared more about 
the future of dermatology than Irwin 
Freedberg. He passionately worried, 
fretted, cajoled, exhorted, and inspired 
us to be mindful of the changes affect-
ing our field and those that will affect 
us for years to come. Many knew 
Irwin as a scientist, a chairman, and 
an organizational leader, but his eyes 
also lit up as he thought about the 
types of people who would be prac-
ticing dermatology in the future, the 
survival of the institutions where they 
would train, the types of practices they 
would create, and their relation to the 
communities in which they worked.
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Chief among his priorities was the 
preservation of academic departments 
of dermatology. He knew they faced 
struggles to recruit and retain faculty. 
Irwin worked tirelessly to support and 
mentor faculty so that the joys and 
rewards of academic practice wouldn’t 
be overrun by bureaucratic, financial, 
and academic challenges. Irwin, how-
ever, did not limit himself to mentoring 
those who worked for him at New York 
University. In fact, the network of his 
mentees is a diverse group that extends 
around the world and across the age 
spectrum. Each of us was at some time 
or another shocked to discover just 
how many people looked to Irwin for 
advice and mentorship — and none of 
us could believe that he found the time 
and energy to give so much to so many. 
He genuinely took pleasure from con-
tributing to the success of others.
One of our first encounters with 
Irwin was an impassioned debate 
over when residency graduates should 
study for and take their board exams 
before moving on with their lives. 
Irwin’s long-held opinion was that ear-
lier board exams would mean distract-
ed trainees, preoccupied with studying 
during the final months of residency. 
Even though we were just upstart 
trainees seated with him for dinner 
at an American Medical Association 
meeting, he listened carefully and, 
by the end of the evening, declared 
humorously that “residents in their last 
months of training don’t do a damned 
thing anyway,” and that they might as 
well be studying for boards. Within a 
year, the certifying exam was moved 
from October to August.
We came to look forward to those 
dinners with the dermatology delega-
tion at American Medical Association 
meetings every December and June and 
the years of wide-ranging conversations 
steeped in the history of dermatology 
and the issues facing it. The conversa-
tions frequently returned to the issue 
of the dermatology work force. Even 
though the hazardous business of work 
force projections was a far cry from the 
basic sciences in which he was so well 
versed, Irwin didn’t hesitate to dive into 
the subject (and share his opinions). 
With his broad perspective and analytic 
insight, he saw that change was afoot 
— and that he could be part of that 
change. For example, having observed 
that growing pressures of private prac-
tice were resulting in a decline in the 
willingness of community dermatolo-
gists to serve as volunteer faculty, Irwin 
took action. For the last two years of his 
life, he required New York University 
residency applicants to sign a pledge 
promising to give back by volunteering 
their time to universities or their com-
munities for a lifetime.
As a role model and mentor, Irwin 
taught us through his comments and 
his actions that there was a right thing 
to do — and that there was a way to do 
it. We’ll miss those dinner conversa-
tions with Irwin, but we know that his 
leadership will continue to shape and 
guide our ideas for years to come.
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How do keratins affect the skin in health 
and disease? In no small part, our abil-
ity to address this question stems from 
Irwin Freedberg’s pioneering work in 
keratin biology (Freedberg, 1993).
But Dr. Freedberg was not, of course, 
just a basic scientist; he was a physi-
cian. Decade after decade, he cared for 
people whose keratins (or lymphocytes, 
or basement membranes, or hair fol-
licles) were misbehaving. He cared not 
only about how keratins affect the skin, 
but also about how the skin affects the 
patient.
Making sense of how an individ-
ual patient is affected by a particular 
skin disease is a clinical imperative. It 
requires a scientific understanding of 
skin disease but is, ultimately, part of 
the art of medicine. It is what we derma-
tologists do — and what Dr. Freedberg 
did — in every patient encounter.
Making sense of how large popula-
tions of patients are affected by skin 
diseases, on the other hand, is a much 
more daunting task. We dermatologists 
have been far more successful in our 
basic-science laboratories and in our 
clinics than we have been in under-
standing, quantifying, and communi-
cating how skin diseases affect large 
populations of patients.
Dr. Freedberg was undaunted. It was 
Dr. Freedberg who chaired the first-
ever Workshop on the Burden of Skin 
Diseases. Mandated by Congress in 
2002 and convened in September 2002 
by the National Institute of Arthritis and 
Musculoskeletal and Skin Diseases, its 
other participants included academic 
dermatologists, clinicians and scientists 
from the National Institutes of Health 
and the Centers for Disease Control 
and Prevention, and representatives of 
patient-advocacy organizations. The 
workshop aimed to define what the 
“burden of skin diseases” means; to 
assess our current ability to understand 
and quantify the burden of skin diseas-
es; to identify areas in which our abil-
ity to do so was deficient; and to offer 
recommendations for future research in 
the area.
Published in 2004, the workshop’s 
report (Qureshi et al., 2004) serves as 
an outstanding road map for a popula-
tion-based approach to understanding 
skin disease. It starts by emphasizing 
the importance of addressing basic 
questions — “How is skin disease 
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